Japan at a glance
- Population
- 123.4 million 2025
- Life expectancy at birth
- 84.0 years, 2024
- People aged 65 and over
- 30.0 % of people, 2025
- Health spending per person
- 3,638 US$ per person, 2023
- Doctors
- 2.65 per 1,000 people, 2022
Japan Deep Brain Stimulation Market Industry Trends and Forecast to 2034: Segmented by (Product, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$116.6 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $83.0 Mn | — | — |
| 2025 (base) | $90.9 Mn | +$8.0 Mn | — |
| 2026 (forecast) | $99.7 Mn | +$8.7 Mn | +9.6% |
| 2027 (forecast) | $109.2 Mn | +$9.6 Mn | +20.1% |
| 2028 (forecast) | $119.7 Mn | +$10.5 Mn | +31.7% |
| 2029 (forecast) | $131.2 Mn | +$11.5 Mn | +44.3% |
| 2030 (forecast) | $143.8 Mn | +$12.6 Mn | +58.1% |
| 2031 (forecast) | $157.6 Mn | +$13.8 Mn | +73.3% |
| 2032 (forecast) | $172.7 Mn | +$15.1 Mn | +90% |
| 2033 (forecast) | $189.3 Mn | +$16.6 Mn | +108.2% |
| 2034 (forecast) | $207.5 Mn | +$18.2 Mn | +128.2% |
Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
Deep brain stimulation places thin wires in the brain connected to a pacemaker-like device, to treat Parkinson's, tremor and other conditions.
Key segments of the deep Brain Stimulation market include product (Single-Channel, Dual-Channel and Rechargeable) and indication (Parkinson's, Essential Tremor and Dystonia).
An ageing population, more people living with brain and nerve diseases, better diagnosis and the first disease-modifying treatments are driving the deep Brain Stimulation market.
Biomarker-guided treatment, earlier diagnosis and new device-based therapies give the deep Brain Stimulation market strong room to grow.
Hard-to-reach brain targets, high failure rates in trials, side effects and high prices for new therapies hold back the deep Brain Stimulation market.
The deep Brain Stimulation market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Medical devices are notified, certified or approved depending on their risk; the Pharmaceuticals and Medical Devices Agency (PMDA) reviews higher-risk devices for approval by the Ministry of Health, Labour and Welfare.[1] Everyone is covered by public health insurance, and the Ministry of Health, Labour and Welfare sets the official price list for covered medicines (NHI prices).[2]
[1] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.
[2] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how deep Brain Stimulation products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Japan.
What doctors and scientists are doing in Deep Brain Stimulation right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 13 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 13 Nov 2026.
[4] PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
From our blog
Japan · 1 shared keyword
Japan
Japan
Japan
Japan
Japan
Pharmaceuticals · Japan
Pharmaceuticals · Japan
Pharmaceuticals · Japan
Healthcare Services · Japan
Pharmaceuticals · Japan
Pharmaceuticals · Japan